Graft-versus-Host Disease (GvHD)

Management of complication following stem cell transplant.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
HaematologyTransplant MedicineDermatology

Clinical Guidelines

NICE guideline [TA1054]: Ruxolitinib for treating acute graft versus host disease
National
NICE guideline [TA949]: Belumosudil for treating chronic graft-versus-host disease
National
ANZTCT consensus position statement on ruxolitinib in steroid-refractory and dependent acute and chronic graft-versus-host disease
Local
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD
Local
Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD
Local
EBMT-NIH-CIBMTR Task Force position statement on standardized documentation of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation
Local
German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy
Local
Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation
Local
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Staging
Local
MASCC/ISOO Clinical Practice Statement: Management of oral chronic graft-versus-host disease
Local
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 2014 Report
Local
Updated consensus of the EBMT: Prophylaxis and management of post-transplant GvHD
Local